Stay updated with breaking news from 89bio Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
89bio (NASDAQ: ETNB) has recently received a number of price target changes and ratings updates: 3/6/2024 – 89bio had its price target raised by analysts at Evercore ISI from $29.00 to $37.00. They now have an “outperform” rating on the stock. 3/5/2024 – 89bio had its “market perform” rating reaffirmed by analysts at Oppenheimer Holdings […]
Hopes raised by the phase IIb Harmony study with FGF21 analogue efruxifermin (EFX) in pre-cirrhotic nonalcoholic steatohepatitis (NASH), which appeared in a scientific journal last week, were less than fulfilled as Akero Therapeutics Inc. rolled out disappointing 36-week results from another, same-stage trial called Symmetry in NASH patients with cirrhosis. The company is forging ahead with U.S. FDA talks to figure out how a phase III effort might be designed.
Here are the biggest calls on Wall Street on Monday.
Stock Analysts’ updated eps estimates for Sunday, July 2nd: Coats Group (OTCMKTS:CGGGF) had its target price cut by Jefferies Financial Group Inc. from GBX 102 ($1.30) to GBX 97 ($1.23). 89bio (NASDAQ:ETNB) had its target price raised by BTIG Research from $30.00 to $37.00. Interpublic Group of Companies (NYSE:IPG) had its price target boosted by […]
Research Analysts’ updated eps estimates for Sunday, March 26th: Activision Blizzard (NASDAQ:ATVI) had its target price boosted by Citigroup Inc. from $88.00 to $91.00. Brainstorm Cell Therapeutics (NASDAQ:BCLI) was downgraded by analysts at StockNews.com from a hold rating to a sell rating. 89bio (NASDAQ:ETNB) had its target price boosted by Bank of America Co. from […]